Retail Sales (B2B) was CV Sciences’s largest revenue line in fiscal 2025, bringing in $7.74M of $13.79M (56%).
| Contract with Customer, Sales Channel | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Retail Sales (B2B) | $9.04M | $9.18M | $8.77M | $7.74M | |||
| Retail - Natural Products & Other | — | — | — | — | |||
| E-Commerce Sales (B2C) | $7.17M | $6.83M | $6.94M | $6.05M | |||
| E-Comm | — | — | — | — | |||
| Retail - Fdm | — | — | — | — | |||
| Total | $16.21M | $16.00M | $15.71M | $13.79M |
CV Sciences brought in $13.79M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 12.2% from $15.71M in fiscal 2024. Retail Sales (B2B) was the largest at $7.74M (56.1%), ahead of E-Commerce Sales (B2C) at $6.05M (43.9%).
Compared with fiscal 2024, Retail Sales (B2B) fell 11.7% to $7.74M and E-Commerce Sales (B2C) fell 12.8% to $6.05M. From fiscal 2022 to 2025, combined revenue from these revenue lines fell from $16.21M to $13.79M, a compound annual decline of 5.2%. Retail Sales (B2B)'s share held steady at about 56.1%.
CV Sciences (CVSI) reports its revenue by contract with customer, sales channel. In fiscal 2025, Retail Sales (B2B) was its largest revenue line, bringing in $7.74M (56.1% of the total), followed by E-Commerce Sales (B2C) at $6.05M (43.9%).
Retail Sales (B2B) was CV Sciences' largest revenue line in fiscal 2025, bringing in $7.74M, or 56.1% of the $13.79M total across its two revenue lines.
Every figure comes from CV Sciences' annual financial filings, as reported. Each line keeps the name CV Sciences gives it, and years follow its fiscal calendar.
CV Sciences' revenue by contract with customer, sales channel goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.